Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).
A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Guang'anmen Hospital
-
Contact:
- Quan Jiang
-
Guangzhou, China
- The First People's Hospital of Guangzhou
-
Contact:
- Xiaoyan Cai
-
Jinzhong, China
- The First People's Hospital of Jinzhong
-
Nanchong, China
- Nanchong Central Hospital
-
Contact:
- Shiquan Shuai
-
Shenzhen, China
- Shenzhen Traditional Chinese Medicine Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 18-65, male or female
- Confirmed diagnosis of Ankylosing Spondylitis
- Syndrome of traditional Chinese medicine is blood stasis syndrome
- ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score)≥2.1
- Visual analogue scale (VAS) for night pain≥4分
- Maintained stable doses of Sulfasalazine, Methotrexate, Leflunomide, etc. for more than 1 month if treating with Slow-Acting Antirheumatic Drugs
- Maintained stable doses of biologics for more than 3 month if treating with biologics
- Not use Nonsteroidal Antiinflammatory Drugs within 2 weeks
- Patients who have not participated in other clinical trials within 4 weeks
- Written informed consent
Exclusion Criteria:
- Pregnant or breastfeeding or who expecting to conceive
- Psoriatic arthritis or Enteropathic arthritis
- AS with iritis or uveitis
- Abnormal liver function
- Abnormal kidney function,high level of Creatinine
- WBC (White Blood Cell)<3.0×10^9/L or with Hematological Disease
- Patients with poor control of hypertension or diabetes
- Acute or chronic infectious diseases
- Severe arrhythmia
- Patients with malignant tumors or with a history of malignant tumors
- Drug allergy
- Patients who had taken Yuxuebi tablet for more than 4 weeks with poor outcome
- Patients who are treating with Traditional Chinese medicine for promoting blood circulation and removing blood stasis
- Alcohol or drug abuse
- Participants who are not suitable for clinical trial under doctors' consideration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Yuxuebi tablet
take 5 tablets once, 3 times a day, for 42(±3)days.
|
0.5g/ tablet
|
|
PLACEBO_COMPARATOR: Placebo tablet
take 5 tablets once, 3 times a day, for 42(±3)days.
|
0.5g/ tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Visual analogue scale (VAS) for night pain
Time Frame: Baseline, at day 7, day 14, day 28, day 42 during treatment
|
Baseline, at day 7, day 14, day 28, day 42 during treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual analogue scale (VAS) for whole day
Time Frame: Baseline, at day 7, day 14, day 28, day 42 during treatment
|
Baseline, at day 7, day 14, day 28, day 42 during treatment
|
|
|
BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)
Time Frame: Baseline, at day 28, day 42 during treatment
|
Baseline, at day 28, day 42 during treatment
|
|
|
BASFI (Bath Ankylosing Spondylitis Functional Index)
Time Frame: Baseline, at day 28, day 42 during treatment
|
Baseline, at day 28, day 42 during treatment
|
|
|
BASMI (Bath Ankylosing Spondylitis Metrology Index)
Time Frame: Baseline, at day 28, day 42 during treatment
|
Baseline, at day 28, day 42 during treatment
|
|
|
Syndrome score of traditional Chinese medicine
Time Frame: Baseline, at day 28, day 42 during treatment
|
The Evaluation Scale of Syndrome score ranges from 0 (best score) to 15 (worst score).
|
Baseline, at day 28, day 42 during treatment
|
|
SF-36 (The Medical Outcomes Study 36-item short-form health survey)
Time Frame: Baseline, at day 42 during treatment
|
Baseline, at day 42 during treatment
|
|
|
ESR (Erythrocyte Sedimentation Rate)
Time Frame: Baseline, at day 14, day 28, day 42 during treatment
|
Baseline, at day 14, day 28, day 42 during treatment
|
|
|
CRP (C-Reactive Protein)
Time Frame: Baseline, at day 14, day 28, day 42 during treatment
|
Baseline, at day 14, day 28, day 42 during treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020005P8A02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.